Keywords: cv, thera, records, 1st-qtr, losses, 5m, california
CV Thera records 1st-qtr 2006 losses of $70.5M
Article | 08 May 2006
California, USA-headquartered drug developer CV Therapeutics, a specialist in the field of chronic cardiovascular diseases, says its first-quarter 2006 losses reached $70.5 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
